### Edgar Filing: Kearney Terrence C - Form 4

Kearney Terro Form 4	ence C											
June 05, 2018	3											
<b>FORM</b>	4									PPROVAL		
	STATES		SECURITIES AND EXCHANGE CC Washington, D.C. 20549					OMB Number:	3235-0287			
Check this if no longe subject to Section 16 Form 4 or Form 5 obligation	<sup>er</sup> <b>STATEM</b> 5. Filed pure <sup>8</sup> Section 17(									January 31, 2005 Estimated average burden hours per response 0.5		
<i>See</i> Instruction 1/(a) of the Fublic Outily Holding Company Act of 1940 30(h) of the Investment Company Act of 1940 1(b).												
(Print or Type R	esponses)											
1. Name and Address of Reporting Person <u>*</u> Kearney Terrence C			2. Issuer Name <b>and</b> Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) C/O VERTE PHARMACI INCORPOR AVENUE	X	4iddle) ΓHERN	3. Date of (Month/Da 06/01/20	-	insaction			X Director Officer (give below)		6 Owner er (specify		
				Amendment, Date Original I(Month/Day/Year)				<ol> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> </ol>				
BOSTON, M	IA 02210							•	More than One Re			
(City)	(State)	(State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1.Title of Security (Instr. 3)		Yansaction Date 2A. Deemed onth/Day/Year) Execution Date, if any (Month/Day/Year)			4. Securit onAcquired Disposed (Instr. 3, Amount	(A) o of (D	r )	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	06/01/2018			A	1,801 (1)	A	\$0	8,430	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Edgar Filing: Kearney Terrence C - Form 4

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number onof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day	Date	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. H Der Sec (In:
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 152.74	06/01/2018		А	3,229	<u>(2)</u>	05/31/2028	Common Stock	3,229	

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>			Relationships						
	Director	10% Owner	Officer	Other					
Kearney Terrence C C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210									
Signatures									
/s/ Stephen Migausky, Attorney-in-Fact	06/05/2018								
**Signature of Reporting Person	Date								

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
- (2) Fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.